Rhythm Pharmaceuticals (RYTM) Accumulated Depreciation & Amortization (2016 - 2025)
Rhythm Pharmaceuticals (RYTM) has disclosed Accumulated Depreciation & Amortization for 9 consecutive years, with $500000.0 as the latest value for Q4 2025.
- On a quarterly basis, Accumulated Depreciation & Amortization fell 28.57% to $500000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $500000.0, a 28.57% decrease, with the full-year FY2025 number at $500000.0, down 28.57% from a year prior.
- Accumulated Depreciation & Amortization was $500000.0 for Q4 2025 at Rhythm Pharmaceuticals, down from $700000.0 in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $900000.0 in Q4 2023 to a low of $500000.0 in Q4 2025.
- A 5-year average of $762400.0 and a median of $816000.0 in 2021 define the central range for Accumulated Depreciation & Amortization.
- Peak YoY movement for Accumulated Depreciation & Amortization: rose 9.8% in 2022, then fell 28.57% in 2025.
- Rhythm Pharmaceuticals' Accumulated Depreciation & Amortization stood at $816000.0 in 2021, then grew by 9.8% to $896000.0 in 2022, then grew by 0.45% to $900000.0 in 2023, then decreased by 22.22% to $700000.0 in 2024, then dropped by 28.57% to $500000.0 in 2025.
- Per Business Quant, the three most recent readings for RYTM's Accumulated Depreciation & Amortization are $500000.0 (Q4 2025), $700000.0 (Q4 2024), and $900000.0 (Q4 2023).